In Plain English:
Pentapeptide-18, sold under the trade name Leuphasyl®, is a five-amino-acid peptide designed to copy how your brain's natural pain-calming molecules (enkephalins) quiet overactive nerves. When applied to skin, it latches onto the same receptor sites on motor nerve endings that natural enkephalins do. That receptor signal closes calcium gates inside the nerve, which means fewer neurotransmitter packets get released into the gap between nerve and muscle. With less acetylcholine crossing that gap, the muscle contracts a little less forcefully — and the crease it forms in the overlying skin becomes shallower. In a 28-day manufacturer-sponsored trial it reduced forehead and eye-area wrinkle depth by about 11–12% on its own and jumped to 25% when combined with Argireline (which blocks a different, downstream step in the same signalling chain). It was developed by Lipotec S.A. in Barcelona (now part of Lubrizol Life Science) and first described in a proprietary June 2005 technical dossier supporting the Leuphasyl® brand name.
Research Maturity
Limited Human (<15 PubMed-indexed results for Leuphasyl / pentapeptide-18; no independent RCT+ Studies)
Focus
Aesthetic Dermatology
Cosmeceuticals
Wrinkle Appearance
Origin
Synthesized by Lipotec S.A., Barcelona, Spain (now Lubrizol Life Science). Trade name Leuphasyl® first described in proprietary dossier PD080 (June 2005). INCI name Pentapeptide-18; CAS 64963-01-5; EINECS 214-254-7; FDA UNII PO4D55T1IG; PubChem CID 10099522. Sequence derived from [D-Ala²]-leucine-enkephalin, a degradation-resistant analogue of the endogenous neuropeptide Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) first isolated by Hughes et al. 1975. The D-Ala substitution at position 2 replaces the natural Gly-Gly dipeptide segment, conferring resistance to enkephalinase proteolysis while preserving delta-opioid receptor affinity.
Mechanism
Acts as a presynaptic neuromodulator at the cutaneous neuromuscular junction. Step 1: the peptide sequence Tyr-D-Ala-Gly-Phe-Leu binds delta-opioid (enkephalin) receptors on the extracellular surface of motor nerve terminals. Step 2: receptor occupation triggers dissociation of inhibitory G-protein subunits (Gα, Gβγ). Step 3: Gβγ subunits close voltage-gated Ca²⁺ channels (N- and P/Q-type) and open inward-rectifier K⁺ channels, hyperpolarising the terminal and reducing calcium influx. Step 4: lower intracellular Ca²⁺ decreases the probability of synaptic vesicle fusion with the presynaptic membrane, attenuating acetylcholine exocytosis. Step 5: with less acetylcholine crossing the synaptic cleft, muscle contraction force diminishes, reducing the mechanical compression that forms dynamic expression wrinkles. Crucially distinct from SNARE-complex inhibitors (Argireline, SNAP-8): Leuphasyl operates upstream of vesicle docking, enabling additive or synergistic effects when co-formulated. A 2026 computational study (Akhan et al., PMID 41722287) further identified interactions with TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB pathways via DFT, molecular docking, and dynamics simulations, suggesting anti-aging effects beyond the neuromodulatory mechanism, including modulation of skin elasticity and hydration at the molecular level.
Outcome
Manufacturer-sponsored, 28-day, active-controlled in vivo trial (43 female volunteers, twice-daily topical application, silicon-imprint profilometry): 5% Leuphasyl® solution (0.05% active peptide) alone reduced expression wrinkle depth by 11.64%; 5% Argireline® solution (0.05% acetyl hexapeptide-3) alone reduced by 16.26%; combination of both at equal concentrations reduced by 24.62% — demonstrating an additive/synergistic effect attributable to complementary mechanisms at two points in the neurotransmission cascade (Gorouhi & Maibach, Int J Cosmet Sci 2009, DOI 10.1111/j.1468-2494.2009.00490.x). Manufacturer technical data (Lipotec PD080, 2005) additionally report up to 47% maximum wrinkle reduction with a 5% Leuphasyl + 5% Argireline combination at the 28-day endpoint in a subset of subjects. Animal model data (frontal and periorbital regions) showed 34.7% and 28.4% reductions respectively under controlled conditions. A 2026 spectroscopic and computational analysis (Akhan et al., Comput Biol Chem, PMID 41722287) confirmed biophysical properties of the peptide capable of influencing cellular aging processes at the molecular level. No independent peer-reviewed RCT using Leuphasyl as a sole active has been published; the evidence base is predominantly manufacturer-sponsored.
